respiratori
syncyti
viru
rsv
recent
renam
human
orthopneumoviru
import
viral
respiratori
pathogen
infant
children
adult
patient
immunodefici
cardiopulmonari
diseas
recogn
major
threat
elderli
popul
rsv
infect
start
typic
commoncold
like
symptom
may
progress
seriou
lower
respiratori
tract
infect
associ
high
rate
hospit
infant
children
elderli
vaccin
therapeut
avail
except
also
known
human
antibodi
palivizumab
palivizumab
sole
use
passiv
immun
highrisk
infant
target
specif
highli
conserv
epitop
fusion
protein
result
fusion
inhibit
current
treatment
sever
lower
respiratori
tract
infect
result
rsv
infect
consist
support
care
oxygen
administr
nutrit
rsv
classifi
famili
pneumovirida
genu
orthopneumoviru
divid
two
subtyp
rsva
rsvb
nonseg
neg
singlestrand
rna
genom
consist
ten
gene
encod
protein
viral
envelop
contain
three
protein
attach
protein
g
fusion
protein
f
small
hydrophob
protein
sh
g
protein
interact
cellular
receptor
host
cell
membran
attach
viru
particl
cell
surfac
protein
consist
central
conserv
domain
two
glycosyl
mucinlik
region
ntermin
region
contain
transmembran
domain
cytoplasm
domain
sequenc
g
gene
indic
two
mucinlik
region
flank
central
domain
similar
nucleotid
level
rsva
rsvb
similar
deduc
amino
acid
level
consequ
two
mucinlik
region
serv
excel
target
rsv
evolut
studi
subtyp
divid
genotyp
base
genet
variat
rsva
genotyp
defin
rsvb
thb
genotyp
report
f
protein
respons
fusion
viral
envelop
host
cell
membran
import
side
effect
fusion
cell
membran
infect
cell
adjac
cell
result
giant
cell
multipl
nuclei
better
known
syncytium
format
syncytia
recogn
mean
effici
spread
infect
along
epitheli
surfac
minim
contact
immun
system
one
hallmark
patholog
caus
rsv
infect
increas
mucu
product
lung
infect
individu
mucu
gellik
substanc
consist
differ
mucin
muc
high
molecular
mass
highli
glycosyl
glycoprotein
airway
mucu
protect
epitheli
surfac
injuri
mucociliari
clearanc
facilit
remov
foreign
particl
chemic
enter
lung
twentyon
muc
protein
describ
human
divid
two
famili
secret
mucin
cellteth
mucin
major
mucin
produc
airway
secret
mucin
membranebound
mucin
publish
research
rsv
perform
use
laboratori
strain
rsvlong
rsv
isol
popul
respect
virus
circul
public
mani
year
serial
passag
cell
cultur
may
result
accumul
mutat
benefit
viru
grow
cell
cultur
may
also
affect
virushost
interact
lowpassag
character
clinic
strain
hard
come
consequ
less
use
research
therefor
isol
viru
mucos
secret
patient
winter
season
belgium
result
eight
rsva
subtyp
four
rsvb
subtyp
grown
virus
passag
use
assess
viral
replic
kinet
infecti
viru
product
cell
thermal
stabil
syncytium
format
neutral
palivizumab
also
obtain
g
protein
sequenc
assign
genotyp
evalu
product
mucin
mrna
express
cell
upon
infect
vero
cell
line
obtain
cultur
instruct
atcc
cell
line
gener
gift
dr
ultan
f
power
queen
univers
belfast
ireland
cell
cultur
dulbecco
modifi
eagl
medium
contain
inactiv
fetal
bovin
serum
thermo
fisher
scientif
waltham
usa
rsv
refer
strain
obtain
bei
resourc
rsv
cultiv
cell
describ
van
der
gucht
w
et
al
rsv
cultiv
vero
cell
medium
contain
inactiv
foetal
bovin
serum
ifb
cytopath
effect
cpe
visibl
throughout
flask
viru
collect
describ
rsv
quantifi
convent
plaqu
assay
cell
describ
schepen
et
al
briefli
cell
seed
concentr
cellswel
clear
well
plate
falcon
one
day
prior
infect
cell
wash
dmem
without
ifb
infect
dilut
seri
made
cell
incub
inoculum
replac
contain
fmc
biopolym
incub
three
addit
day
afterward
cell
wash
pb
fix
paraformaldehyd
solut
stain
palivizumab
leftov
provid
depart
paediatr
antwerp
univers
hospit
goatanti
human
secondari
igg
conjug
horseradish
peroxidas
hrp
thermo
fisher
scientif
visual
use
chloronaphtol
solut
thermo
fisher
scientif
studi
approv
ethic
committe
antwerp
univers
hospit
univers
antwerp
nasal
secret
collect
children
show
symptom
rsvrelat
bronchiol
winter
season
written
parent
consent
given
secret
extract
nasal
swab
andor
nasopharyng
aspir
store
less
h
one
day
prior
mucos
extract
cell
seed
concentr
cellswel
clear
well
plate
falcon
corn
ny
usa
sampl
vortex
one
minut
glass
bead
sigmaaldrich
st
loui
mo
usa
inocul
cell
dilut
seri
sampl
made
h
incub
inoculum
dmem
contain
ifb
antibiot
penicillinstreptomycin
thermo
fischer
scientif
moxifloxacin
sigmaaldrich
antifung
fungizon
sigmaaldrich
ad
obtain
final
concentr
dmem
fb
plate
incub
seven
day
seven
day
plate
check
syncytium
format
well
lowest
concentr
origin
sampl
still
present
cpe
transfer
newli
seed
plate
follow
previous
describ
protocol
addit
seven
day
well
recheck
syncytium
format
total
well
present
syncytia
transfer
freshli
seed
incub
cpe
visibl
throughout
cultur
supernat
collect
centrifug
ten
minut
g
aliquot
snap
frozen
liquid
nitrogen
passag
viru
obtain
clinic
sampl
propag
passag
cell
obtain
plaqu
form
unit
pfu
count
high
enough
perform
follow
experi
one
sampl
propag
effici
cell
propag
three
passag
vero
cell
high
pfu
reach
passag
cultur
test
follow
contamin
qpcr
hmpv
rhinoviru
piv
adenoviru
coronaviru
paraechoviru
enteroviru
bocaviru
found
neg
sever
viru
cultur
test
neg
mycoplasma
presenc
sign
bacteri
fungal
presenc
observ
cultur
test
grown
absenc
antibiot
antifung
rna
subtyp
extract
passag
viru
use
qiamp
viral
rna
extract
mini
kit
qiagen
hilden
germani
follow
instruct
manufactur
multiplex
reaction
mix
made
superscript
iii
platinum
onestep
quantit
kit
thermo
fisher
scientif
final
volum
contain
rna
pcr
master
mix
superscript
rtplatinum
taq
polymeras
premix
primerprob
solut
solut
contain
final
concentr
primer
probe
primer
rsva
locat
l
gene
gct
ctt
agc
aaa
gtc
aag
ttg
aat
tcc
gtt
gga
tgg
tgt
rsvqa
probe
ctc
aaczenaaa
gat
caa
ctt
ctg
tca
tcc
agc
iabkfq
primer
rsvb
locat
n
gene
ggc
tct
tag
caa
agt
caa
gtt
caa
tat
tat
ctc
ctg
tac
tac
gtt
rsvqb
probe
tac
att
aaa
taa
gga
tca
gct
gct
gtc
atc
adapt
bragstad
k
reaction
run
realtim
pcr
machin
stratagen
thermo
fisher
scientif
follow
program
min
min
follow
cycl
min
ct
valu
count
posit
viral
rna
extract
infect
cell
cultur
supernat
use
qiamp
viral
rna
mini
kit
qiagen
accord
instruct
provid
manufactur
viral
rna
g
gene
transcrib
cdna
amplifi
use
onestep
rtpcr
kit
qiagen
follow
primer
describ
houspi
et
al
rsva
caa
caa
gcc
aga
tca
atc
aca
ctg
gta
tac
caa
cc
rsvb
bgf
gcc
ata
ata
ttc
atc
atc
bgr
ccc
agr
ttt
aat
ttc
gtt
use
primer
ad
reaction
mix
consist
rtpcr
buffer
dntp
enzym
final
amount
pmol
ten
microlit
rna
extract
ad
reaction
mix
pcr
perform
thermocycl
unocycl
vwr
radnor
pa
usa
follow
program
min
rt
step
min
pcr
activ
amplif
cycl
consist
min
min
follow
final
extens
step
min
length
amplifi
cdna
verifi
agaros
gel
electrophoresi
cdna
visual
vwr
amplifi
cdna
deliv
vib
neurom
support
facil
univers
antwerp
pcr
cleanup
dna
sequenc
follow
primer
describ
houspi
et
al
addit
pcr
amplif
primer
rsva
gct
gca
ggg
tac
aaa
gtt
gaa
tga
ccc
aga
atc
ccc
rsvb
gac
cca
aaa
aca
cya
gcc
ggg
aac
gaa
gtt
gaa
cac
ttc
provid
sequenc
sequenc
annot
snapgen
contig
built
bioedit
applic
multipl
sequenc
align
refer
strain
contig
phylogenet
tree
construct
mega
x
use
maximum
likelihood
method
cell
seed
concentr
cellswel
black
well
plate
flat
bottom
suitabl
fluoresc
microscopi
greinerbio
one
one
day
prior
inocul
briefli
inocul
cell
wash
clinic
rsv
rsv
dilut
infect
cell
multipl
infect
moi
viru
left
adher
h
replac
cell
fix
paraformaldehyd
h
h
h
permeabil
triton
stain
polyclon
goatantirsv
antibodi
virostat
specif
viral
antigen
follow
donkeyantigoat
secondari
antibodi
conjug
alexa
fluor
thermo
fisher
scientif
addit
dapi
nucleu
stain
sigmaaldrich
cell
seed
concentr
cellswel
plate
h
prior
infect
briefli
infect
cell
wash
afterward
infect
clinic
isol
rsv
rsv
moi
supernat
collect
h
h
h
aliquot
snap
frozen
store
supernat
quantifi
use
convent
plaqu
assay
cell
describ
aliquot
clinic
isol
rsv
rsv
thaw
dilut
obtain
start
concentr
pfuml
aliquot
made
sampl
immedi
afterward
one
aliquot
sampl
snap
frozen
liquid
nitrogen
aliquot
store
h
h
h
snap
frozen
liquid
nitrogen
store
quantif
perform
convent
plaqu
assay
cell
describ
use
quantifi
remain
pfu
aliquot
one
day
prior
inocul
cell
seed
concentr
cellswel
black
plate
flat
bottom
suitabl
fluoresc
microscopi
greiner
bioon
cell
inocul
clinic
rsv
rsv
moi
h
inoculum
remov
replac
contain
fmc
biopolym
h
cell
wash
pb
fix
paraformaldehyd
solut
permeabil
triton
stain
polyclon
goatantirsv
virostat
westbrook
usa
follow
donkeyantigoat
secondari
antibodi
conjug
thermo
fisher
scientif
dapi
stain
perform
stain
nuclei
sigmaaldrich
plaqu
reduct
assay
perform
describ
leeman
et
al
briefli
cell
seed
concentr
cellswel
clear
plate
falcon
h
prior
inocul
palivizumab
dilut
dilut
seri
incub
dilut
viru
h
afterward
cell
wash
briefli
inocul
virusantibodi
solut
h
inoculum
replac
contain
fmc
biopolym
plate
incub
three
day
wash
pb
fix
paraformaldehyd
solut
cell
permeabil
triton
stain
palivizumab
antibodi
follow
goatantihuman
igg
conjug
hrp
colour
use
chloronaphtol
solut
thermo
fisher
scientif
neutral
titer
defin
reciproc
highest
antibodi
dilut
produc
reduct
plaqu
rel
viruscontrol
well
without
antibodi
cell
seed
concentr
cellswel
plate
h
prior
inocul
greiner
bioon
cell
infect
moi
h
h
inoculum
replac
incub
addit
h
afterward
cell
supernat
collect
spun
g
min
pellet
kept
still
adher
cell
lyse
lysi
buffer
nucleospin
kit
machereynagel
germani
ad
pellet
solut
thoroughli
mix
frozen
extract
perform
rna
isol
done
follow
manufactur
instruct
nucleospin
rna
kit
machereynagel
concentr
evalu
use
thermo
fisher
scientif
rna
use
convert
cdna
use
cdna
synthesi
kit
biolin
london
uk
rel
gene
express
determin
gotaq
qpcr
master
mix
promega
madison
wi
usa
sybr
green
fluoresc
detect
quantstudio
realtim
pcr
instrument
thermo
fisher
scientif
standard
quantitect
primer
avail
qiagen
use
gapdh
analysi
qualiti
control
perform
use
qbase
softwar
biogazel
ghent
belgium
rel
express
target
gene
normal
express
housekeep
gene
gapdh
fluoresc
imag
acquir
use
axio
observ
invert
microscop
compact
light
sourc
hxp
filter
set
blue
green
red
fluorophor
respect
zeiss
imag
analysi
done
use
zeiss
zen
blue
edit
imag
softwar
imagej
version
calcul
made
excel
mac
graphpad
prism
data
viral
replic
kinet
infecti
viru
product
thermal
stabil
present
mean
sem
indic
independ
repeat
determin
signific
clinic
isol
refer
rsv
data
analys
twoway
anova
fusion
data
muc
express
repres
mean
sem
signific
calcul
clinic
isol
refer
oneway
anova
data
plaqu
reduct
repres
mean
sd
signific
calcul
clinic
isol
refer
oneway
anova
calcul
done
use
graphpad
prism
nasal
swab
nasopharyng
aspir
obtain
one
patient
decemb
patient
octob
januari
rsva
detect
one
sampl
decemb
sampl
collect
octob
januari
rsvb
detect
sampl
collect
octob
januari
remain
two
rsvneg
sampl
one
test
posit
human
metapneumoviru
hmpv
one
remain
neg
rsv
hmpv
rhinoviru
cell
infect
sampl
day
aspir
secret
day
afterward
without
freez
sampl
two
week
incub
sampl
result
syncytium
format
posit
fluoresc
stain
either
nasal
swab
cultur
aspir
cultur
therefor
use
follow
assay
cultur
show
syncytium
format
use
grow
viru
cell
one
sampl
grown
vero
cell
sinc
signific
titer
could
reach
grow
viru
cell
tabl
sequenc
g
gene
sampl
obtain
align
previous
report
repres
sequenc
genbank
phylogenet
tree
rsva
rsvb
sequenc
shown
figur
b
rsva
sequenc
cluster
within
genotyp
contain
duplic
rsvb
sequenc
contain
duplic
ggene
assign
ba
genotyp
differenti
baix
genotyp
studi
dynam
viru
infect
viral
replic
kinet
infecti
viru
product
assess
cell
cell
infect
h
h
h
moi
fix
fluoresc
stain
analys
fluoresc
microscopi
evalu
viral
replic
kinet
infecti
viru
product
evalu
collect
supernat
h
h
h
postinfect
moi
supernat
snap
frozen
use
quantif
via
plaqu
assay
viral
replic
kinet
cell
rsva
figur
strain
yield
one
strain
result
significantli
higher
percentag
rsvinfect
cell
h
compar
rsv
also
produc
infecti
viru
particl
h
post
inocul
pi
compar
strain
figur
three
strain
replic
slowli
rsv
h
fulli
infect
cultur
observ
h
infect
infect
moi
rsvb
strain
result
infect
valu
infect
cell
h
rsvb
strain
figur
show
two
strain
grown
cell
one
strain
grown
vero
cell
result
significantli
infect
cell
h
refer
rsv
wherea
one
strain
seem
result
compar
infect
rsv
infecti
viru
product
rsvb
strain
show
even
though
reach
high
percentag
infect
cell
less
infecti
particl
produc
compar
suggest
either
particl
may
effici
releas
supernat
remain
cellassoci
particl
may
effici
attach
replic
lower
level
experi
repeat
figur
cell
line
rsva
isol
figur
rsv
show
highest
percentag
infect
cell
follow
close
reach
slightli
lower
percentag
infect
cell
cell
h
strain
also
produc
highest
amount
infecti
viru
cell
figur
cell
rsvb
subtyp
isol
reach
higher
percentag
infect
cell
rsv
wherea
result
replic
kinet
suggest
strain
reach
similar
infect
rate
figur
reach
infect
h
infect
seem
flatten
toward
h
result
signific
differ
infect
rate
rsv
interestingli
isol
effici
infect
cell
reach
near
infect
number
cell
h
unsurprisingli
achiev
lowest
number
infect
cell
level
viru
product
cell
figur
cell
line
also
highli
permiss
cell
line
rsv
infect
wide
use
well
assess
viral
growth
product
kinet
cell
line
figur
rsva
clinic
isol
major
differ
observ
h
h
infect
percentag
infect
cell
figur
infect
amount
infecti
viru
releas
cell
highest
rsv
clinic
isol
larger
differ
observ
clinic
isol
rsvb
subtyp
figur
reach
percentag
infecti
viru
product
compar
rsv
figur
isol
lowest
infect
rate
infecti
viru
product
cell
line
well
cell
figur
overal
clinic
isol
replic
effici
cell
line
remark
achiev
even
higher
infect
rate
cell
line
rsv
addit
two
clinic
isol
rsvb
subtyp
replic
well
cell
line
quit
well
overal
differ
infect
kinet
observ
also
among
differ
clinic
isol
differ
f
protein
shown
involv
thermal
stabil
viral
particl
aliquot
viru
contain
pfuml
incub
three
differ
temperatur
vitro
incub
temperatur
core
bodi
temperatur
figur
b
upper
airway
temperatur
figur
storag
temperatur
figur
f
h
h
h
aliquot
snap
frozen
liquid
nitrogen
use
convent
plaqu
assay
quantifi
remain
infecti
viru
rsva
isol
rsv
higher
temperatur
associ
faster
decay
infecti
viru
curious
maintain
higher
pfu
rsva
isol
although
temperatur
differ
addit
preserv
slightli
better
howev
h
viabl
viru
detect
rsvb
isol
retain
higher
titer
durat
experi
compar
rsvb
isol
overal
stabil
less
refer
rsv
except
viral
titer
remain
higher
rsv
isol
seem
decay
especi
fast
temperatur
syncytium
format
long
consid
typic
characterist
rsv
infect
immort
cell
line
use
measur
activ
fusion
protein
cell
infect
moi
incub
h
overlay
contain
allow
spread
infect
neighbour
cell
afterward
cell
fix
fluoresc
stain
analys
fluoresc
microscopi
mean
syncytium
size
determin
calcul
mean
number
nuclei
syncytia
form
per
sampl
figur
b
well
mean
syncytium
frequenc
figur
count
number
nuclei
belong
syncytia
rel
total
number
nuclei
infect
cell
mean
syncytium
size
rsva
clinic
isol
figur
lie
four
seven
nuclei
per
cell
largest
syncytia
smallest
syncytia
produc
mean
syncytium
frequenc
lie
lowest
frequenc
found
suggest
promot
format
larger
syncytia
rather
mani
small
syncytia
figur
clinic
isol
form
significantli
larger
syncytia
mean
size
compar
clinic
isol
figur
refer
strain
rsv
form
almost
syncytia
smallest
size
lowest
frequenc
virus
test
viral
neutral
palivizumab
assess
convent
plaqu
reduct
assay
viru
incub
twofold
dilut
seri
palivizumab
transfer
cell
allow
infect
nonneutr
viru
afterward
supernat
replac
contain
incub
three
day
plaqu
visibl
nake
eye
plaqu
count
determin
concentr
palivizumab
neutral
viru
figur
show
rsva
clinic
isol
neutral
lower
palivizumab
concentr
clinic
isol
rsv
result
better
neutral
isol
remark
rsv
rsv
neutral
significantli
differ
rsvb
strain
higher
sensit
palivizumab
rsva
strain
overal
signific
differ
observ
rsvb
clinic
isol
refer
rsv
palivizumab
neutral
rsv
infect
hallmark
increas
mucu
product
impair
mucociliari
clearanc
import
player
secret
airway
mucin
cellteth
mucin
mrna
express
level
upon
rsv
infect
cell
test
mrna
express
level
mucin
assess
infect
cell
h
moi
follow
qrtpcr
primer
differ
mucinencod
gene
cell
incub
viru
isol
h
inoculum
remov
replac
cell
incub
h
collect
lysi
follow
rna
extract
qrtpcr
clinic
isol
control
rel
express
cellteth
figur
increas
compar
noninfect
control
signific
differ
howev
observ
rsv
isol
control
express
profil
cellteth
show
consider
rel
increas
compar
neg
control
figur
infect
result
highest
rel
increas
mrna
among
rsva
clinic
isol
wherea
result
lowest
increas
rsvb
clinic
isol
significantli
lower
increas
observ
compar
rsva
clinic
isol
increas
still
observ
infect
isol
result
highest
increas
mrna
express
among
rsvb
isol
mainli
produc
epitheli
goblet
cell
previous
report
slightli
decreas
cell
influenc
rsvinfect
express
significantli
reduc
upon
infect
clinic
isol
refer
strain
howev
signific
differ
observ
clinic
isol
figur
produc
surfac
secretori
cell
throughout
airway
submucos
gland
result
show
express
downregul
result
rsv
infect
strongest
downregul
rsva
clinic
isol
overal
downregul
rsvb
clinic
isol
limit
almost
none
infect
figur
isol
rsv
nasal
sampl
patient
winter
season
found
isol
infecti
viru
nasal
sampl
effici
nasopharyng
aspir
compar
nasopharyng
swab
howev
yield
may
also
depend
time
sampl
compar
onset
symptom
time
sampl
inocul
cell
cultur
cell
use
isol
sinc
permiss
rsv
strain
isol
describ
one
wellknown
except
rsv
infect
cell
viral
titer
remain
low
compar
strain
howev
infect
rsv
vero
cell
yield
higher
titer
also
case
clinic
isol
studi
clinic
isol
genotyp
character
abil
grow
produc
infecti
viru
cell
line
thermal
stabil
assess
normal
bodi
temperatur
incub
temperatur
estim
nasal
temperatur
storag
temperatur
fusion
capac
neutral
palivizumab
specif
featur
fusion
protein
mucin
mrna
express
cellteth
mucin
secret
mucin
even
though
rsva
rsvb
clinic
isol
belong
genotyp
phylogenet
tree
baix
respect
result
show
differ
differ
isol
accord
phylogenet
tree
clinic
isol
divid
three
group
rsva
isol
two
group
rsvb
isol
howev
differ
even
observ
clinic
isol
belong
group
within
genotyp
exampl
comparison
clinic
isol
season
infect
higher
number
cell
viral
replic
kinet
experi
produc
higher
amount
infecti
viru
retain
stabil
thermal
stabil
assay
slightli
less
neutral
palivizumab
compar
rsva
clinic
isol
isol
season
secondli
gener
poor
infector
also
lower
thermal
stabil
rsvb
clinic
isol
season
gener
differ
observ
differ
clinic
isol
viral
replic
kinet
clinic
isol
abil
infect
cell
line
test
differ
could
due
underli
genet
differ
could
affect
antivir
respons
cell
due
differ
could
account
chang
way
viru
replic
cell
presenc
defect
interf
viru
particl
result
suggest
thermal
stabil
clinic
isol
gener
lower
refer
strain
reason
unknown
may
repeat
infect
refer
strain
result
select
variant
replic
fit
advantag
temperatur
remark
rsv
remain
rather
stabl
compar
rsv
clinic
strain
f
protein
indispens
viru
infect
activ
link
format
syncytia
mean
syncytium
size
mean
syncytium
frequenc
determin
infect
overlay
minim
free
particl
movement
presenc
would
promot
format
syncytia
rather
spread
format
new
syncytia
incub
period
even
minim
free
particl
movement
differ
size
syncytia
contain
nuclei
per
cell
form
clinic
isol
exampl
clearli
form
larg
syncytia
without
infect
satellit
cell
suggest
produc
particl
remain
cell
associ
viru
spread
cell
may
facilit
syncytia
format
rather
particl
releas
could
also
observ
replic
kinet
infecti
viru
product
number
infect
cell
rapidli
increas
cultur
infect
wherea
amount
infecti
viru
supernat
lower
compar
clinic
isol
suggest
product
infecti
viru
particl
either
limit
faulti
cell
isol
full
character
product
defect
interf
particl
could
provid
explan
test
neutral
clinic
isol
palivizumab
monoclon
antibodi
current
use
passiv
immun
infant
risk
factor
sever
rsvrelat
respiratori
infect
curious
rsvb
isol
rsv
better
neutral
rsva
clinic
isol
increas
mucu
product
airway
import
characterist
defenc
mechan
bodi
protect
airway
respiratori
infect
shown
express
profil
mucin
mrna
chang
influenc
rsv
infect
rel
express
increas
infect
cell
compar
noninfect
control
wherea
rel
express
decreas
infect
cell
compar
neg
control
observ
differ
characterist
virus
isol
children
one
rsv
season
vitro
viral
replic
kinet
cell
line
infecti
viru
product
thermal
stabil
fusion
capac
neutralizationsensit
addit
mucin
mrna
express
assess
reveal
gener
minor
differ
differ
clinic
isol
furthermor
comparison
clinic
isol
refer
strain
rsv
rsv
reveal
overal
major
differ
clinic
isol
replic
either
faster
slower
cell
line
gener
lower
thermal
stabil
differ
fusion
capac
mucin
express
